The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
Open accessAbstract
BACKGROUND: The long-term effects of sibutramine treatment on the rates of cardiovascular events and cardiovascular death among subjects at high cardiovascular risk have not been established. METHODS: We enrolled in our study 10,744 overweight or obese subjects, 55 years of age or older, with preexisting cardiovascular disease, type 2 diabetes mellitus, or both to assess the cardiovascular consequences of weight management with and without sibutramine in subjects at high risk for cardiovascular events. All the subjects received sibutramine in addition to participating in a weight-management program during a 6-week, single-blind, lead-in period, after which 9804 subjects underwent random assignment in a double-blind fashion to sibutramine (4906 subjects) or placebo (4898 subjects). The primary end point was the time from randomization to the first occurrence of a primary outcome event (nonfatal myocardial infarction, nonfatal stroke, resuscitation after cardiac arrest, or cardiovascular death). RESULTS: The mean duration of treatment was 3.4 years. The mean weight loss during the lead-in period was 2.6 kg; after randomization, the subjects in the sibutramine group achieved and maintained further weight reduction (mean, 1.7 kg). The mean blood pressure decreased in both groups, with greater reductions in the placebo group than in the sibutramine group (mean difference, 1.2/1.4 mm Hg). The risk of a primary outcome event was 11.4% in the sibutramine group as compared with 10.0% in the placebo group (hazard ratio, 1.16; 95% confidence interval [CI], 1.03 to 1.31; P=0.02). The rates of nonfatal myocardial infarction and nonfatal stroke were 4.1% and 2.6% in the sibutramine group and 3.2% and 1.9% in the placebo group, respectively (hazard ratio for nonfatal myocardial infarction, 1.28; 95% CI, 1.04 to 1.57; P=0.02; hazard ratio for nonfatal stroke, 1.36; 95% CI, 1.04 to 1.77; P=0.03). The rates of cardiovascular death and death from any cause were not increased. CONCLUSIONS: Subjects with preexisting cardiovascular conditions who were receiving long-term sibutramine treatment had an increased risk of nonfatal myocardial infarction and nonfatal stroke but not of cardiovascular death or death from any cause. (Funded by Abbott; ClinicalTrials.gov number, NCT00234832.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Early weight loss medications, such as fenfluramine (Fen-Phen) and sibutramine, were withdrawn due to severe cardiovascular and psychiatric side effects [3,4].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite 5–10% weight loss in trials, it was discontinued in 2010 after the SCOUT trial showed elevated cardiovascular events (e.g., stroke) in high-risk patients [4].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“the concept of treating obesity to reduce the risk of cardiovascular complications has been hampered by the lack of evidence from trials indicating that lifestyle or pharmacologic interventions for overweight or obesity improve cardiovascular outcomes. 11-15”
From Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (2023) · cites this paper as [13]
In the citing paper
“Prospective studies that evaluated the effect of nonsurgical weight loss interventions on CV event reduction have been disappointing [4, 5, 6, 7, 8].”
From Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics (2023) · cites this paper as [5]
In the citing paper
“Specifically, across the obesity CVOTs, SELECT is the only study to our knowledge that only enrolled participants with established CVD, whereas in the other obesity CVOTs, 24.9% to 50.5% of participants had no prior events [5, 6, 7, 8].”
From Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics (2023) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Prospective Studies Collaboration (2009) · The Lancet · doi:10.1016/s0140-6736(09)60318-4 · Cited by 4,807
Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects
Sjöström, L., Narbro, K., Sjöström, C. D., Karason, K., Larsson, B., Wedel, H., Lystig, T., Sullivan, M., Bouchard, C., Carlsson, B., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066254 · Cited by 4,668
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
Long-term mortality after gastric bypass surgery
Adams, T. D., Gress, R. E., Smith, S. C., Halverson, R. C., Simper, S. C., Rosamond, W. D., LaMonte, M. J., Stroup, A. M., & Hunt, S. C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066603 · Cited by 2,572
S UCCESSFUL W EIGHT L OSS M AINTENANCE
Wing, R. R., & Hill, J. O. (2001) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.21.1.323 · Cited by 1,382
Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis
Dattilo, A., & Kris-Etherton, P. (1992) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/56.2.320 · Cited by 1,055
Secular Trends in Cardiovascular Disease Risk Factors According to Body Mass Index in US Adults
Gregg, E. W. (2005) · JAMA · doi:10.1001/jama.293.15.1868 · Cited by 959
Blood Pressure Lowering Treatment Trialists’ Collaboration (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.12.1410 · Cited by 789
Flagged first, then by citations
Research works printed but not linked: 3
- 1996, Can J Cardiol, 12, 127
- 1994, Lancet, 344, 1383
- Lyznicki JM, 2001, Am Fam Physician, 63, 2185
Cited by
Sorted by citations
Items 301–400 of 943
Cardiovascular Effects of the New Weight Loss Agents
Vorsanger, M., Subramanyam, P., WEINTRAUB, H. S., Lamm, S. H., Underberg, J. A., Gianos, E., Goldberg, I. J., & Schwartzbard, A. Z. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.06.007 · Cited by 33
Targets for Medical Therapy in Obesity
Baretić, M. (2012) · Digestive Diseases · doi:10.1159/000336672 · Cited by 31
Cardiovascular safety of naltrexone and bupropion therapy: Systematic review and meta‐analyses
Sposito, A. C., Bonilha, I., Luchiari, B., Benchimol, A. K., Hohl, A., Moura, F., Cercato, C., Geloneze, B., Nadruz, W., Aguilar-Salinas, C. A., et al. (2021) · Obesity Reviews · doi:10.1111/obr.13224 · Cited by 31
Conde, K., Fang, S., & Xu, Y. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01091-7 · Cited by 33
Park, S., Nahmkoong, W., Cheon, C., Park, J.-S., Jang, B.-H., Shin, Y. C., Kim, K., Go, H.-Y., Song, Y.-K., & Ko, S. (2013) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2013/498935 · Cited by 31
Cost-Effectiveness of Pharmacotherapy to Reduce Obesity
Veerman, L. J., Barendregt, J. J., Forster, M., & Vos, T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026051 · Cited by 30
Seimon, R. V., Espinoza, D., Ivers, L., Gebski, V., Finer, N., Legler, U. F., Sharma, A. M., James, W. P. T., Coutinho, W. F., & Caterson, I. D. (2014) · International Journal of Obesity · doi:10.1038/ijo.2014.2 · Cited by 31
Self-citationRegulatory alerts for dietary supplements in Canada and the United States, 2005–13
Abe, A. M., Hein, D. J., & Gregory, P. J. (2015) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp140574 · Cited by 30
El-Solh, A., Gould, E., Aibangbee, K. E., Jimerson, T., & Hartling, R. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2437525 · Cited by 31
The unrelenting fall of the pharmacological treatment of obesity
Dalmazi, G. D., Vicennati, V., Pasquali, R., & Pagotto, U. (2013) · Endocrine · doi:10.1007/s12020-013-9983-1 · Cited by 29
Hemdan, A. M., & Tawakkol, S. M. (2018) · Chromatographia · doi:10.1007/s10337-018-3502-8 · Cited by 29
Fatty acids role on obesity induced hypothalamus inflammation: From problem to solution – A review
Salsinha, A. S., Rodríguez-Alcalá, L. M., Relvas, J. B., & Pintado, M. (2021) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2021.03.042 · Cited by 29
Obesity Pharmacotherapy: Current Perspectives and Future Directions
Misra, M. (2013) · Current Cardiology Reviews · doi:10.2174/157340313805076322 · Cited by 29
Emerging drugs for the treatment of obesity
Martinussen, C., Bojsen-Møller, K. N., Svane, M. S., Dejgaard, T. F., & Madsbad, S. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2017.1269744 · Cited by 28
No Guts, No Loss: Toward the Ideal Treatment for Obesity in the Twenty-First Century
Hope, D. C. D., Tan, T., & Bloom, S. R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00442 · Cited by 31
Bays, H. E. (2011) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.10.22 · Cited by 28
The Great Debate: Medicine or Surgery
Lautz, D. B., Halperin, F., GOEBEL-FABBRI, A. E., & Goldfine, A. B. (2011) · Diabetes Care · doi:10.2337/dc10-1859 · Cited by 28
Barriers and Solutions for Prescribing Obesity Pharmacotherapy
Fujioka, K., & Harris, S. R. (2020) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2020.02.007 · Cited by 27
Lim, Y. Y., Lee, Y. S., & Ooi, D. S. Q. (2020) · Biotechnology Journal · doi:10.1002/biot.202000013 · Cited by 26
Page‐Wilson, G., Wardlaw, S. L., Khandji, A. G., & Körner, J. (2011) · Pituitary · doi:10.1007/s11102-011-0349-5 · Cited by 28
Koiou, E., Τζιόμαλος, Κ., Katsikis, I., Kandaraki, E., Kalaitzakis, E., Delkos, D., Vosnakis, C., & Panidis, D. (2011) · Gynecological Endocrinology · doi:10.3109/09513590.2011.588745 · Cited by 28
Role of Neuro-Immune Cross-Talk in the Anti-obesity Effect of Electro-Acupuncture
Lu, M., He, Y., Gong, M., Li, Q., Tang, Q., Wang, X., Wang, Y., Yuan, M., Yu, Z. H., & Xu, B. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00151 · Cited by 28
A narrow view of optimal weight for health generates the obesity paradox
Dixon, J. B., & Egger, G. J. (2014) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.114.086470 · Cited by 29
Management of obesity and cardiometabolic risk – role of phentermine/extended release topiramate
Caterson, I. D., Sweeting, A., Tabet, E. J., & Markovic, T. (2014) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s38979 · Cited by 27
Self-citationCurrent and Emerging Therapies for Non-alcoholic Fatty Liver Disease
Patel, S. S., & Siddiqui, M. S. (2018) · Drugs · doi:10.1007/s40265-018-1040-1 · Cited by 27
Comoglio, R. H. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14179 · Cited by 28
Adulterated Traditional-Herbal Medicinal Products and Its Safety Signals in Malaysia
Ariffin, S. H., Wahab, I. A., Hassan, Y., & Wahab, M. S. A. (2021) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s305953 · Cited by 27
Drug Treatment for Obesity in the Post-Sibutramine Era
Cheung, B. M. Y. (2011) · Drug Safety · doi:10.2165/11592040-000000000-00000 · Cited by 27
Katsiki, N., Hatzitolios, A. I., & Mikhailidis, D. P. (2011) · Annals of Medicine · doi:10.3109/07853890.2010.541490 · Cited by 27
Epidemiology of Obesity and Pharmacologic Treatment Options
Shettar, V., Patel, S., & Kidambi, S. (2017) · Nutrition in Clinical Practice · doi:10.1177/0884533617713189 · Cited by 26
Obesity at Menopause: An Expanding Problem
Atapattu, P. M. (2015) · Journal of Patient Care · doi:10.4172/2573-4598.1000103 · Cited by 27
Moon, S. H., & Kim, M. Y. (2018) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v17i5.22 · Cited by 26
Lorcaserin for the treatment of obesity
Redman, L. M., & Ravussin, É. (2010) · Drugs of today · doi:10.1358/dot.2010.46.12.1556433 · Cited by 29
Risks associated with fat burners: A toxicological perspective
Jakopin, Ž. (2018) · Food and Chemical Toxicology · doi:10.1016/j.fct.2018.10.051 · Cited by 41
Genova, E. C., Cavion, F., Lucafò, M., Leo, L. D., Pelin, M., Stocco, G., & Decorti, G. (2019) · World Journal of Stem Cells · doi:10.4252/wjsc.v11.i12.1020 · Cited by 26
Investigational glucagon-like peptide-1 agonists for the treatment of obesity
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1221925 · Cited by 25
Potential use of exenatide for the treatment of obesity
Folli, F., & Guardado Mendoza, R. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.630660 · Cited by 26
Amodeo, G., Cuomo, A., Bolognesi, S., Goracci, A., Trusso, M. A., Piccinni, A., Neal, S. M., Baldini, I., Federico, E., Taddeucci, C., et al. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1571041 · Cited by 25
Current pharmacotherapy for obesity: extrapolation of clinical trials data to practice
Gadde, K. M. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.890590 · Cited by 26
Translational Pharmacology and Physiology of Brown Adipose Tissue in Human Disease and Treatment
Larson, C. J. (2018) · Handbook of experimental pharmacology · doi:10.1007/164_2018_184 · Cited by 26
Chan, D. L., Cruz, J. R., Mui, W. L., Wong, S. K., & Ng, E. K. (2020) · Obesity Surgery · doi:10.1007/s11695-020-04986-3 · Cited by 25
Han, H.-S., Lee, H.-H., Gil, H.-S., Chung, K., Kim, J.-K., Kim, D., Yoon, J., Chung, E. K., Lee, J. K., Yang, W. M., et al. (2021) · Food & Function · doi:10.1039/d0fo02185g · Cited by 25
Emerging pharmacotherapy for obesity
Aronne, L. J., Powell, A. G., & Apovian, C. M. (2011) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2011.609168 · Cited by 26
Treatment of Obesity-Related Hypertension in Children and Adolescents
Halbach, S. M., & Flynn, J. T. (2013) · Current Hypertension Reports · doi:10.1007/s11906-013-0334-7 · Cited by 25
Association of anemia with the risk of cardiovascular adverse events in overweight/obese patients
Winther, S. A., Finer, N., Sharma, A. M., Torp-Pedersen, C. T., & Andersson, C. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.111 · Cited by 24
Self-citationTreatment of Obesity in Young People—a Systematic Review and Meta-analysis
Selvendran, S. S., Penney, N. C., Aggarwal, N., Darzi, A. W., & Purkayastha, S. (2018) · Obesity Surgery · doi:10.1007/s11695-018-3285-x · Cited by 26
Therapeutic prospects of metabolically active brown adipose tissue in humans
Betz, M. J. (2011) · Frontiers in Endocrinology · doi:10.3389/fendo.2011.00086 · Cited by 24
Ghotbi, A. A., Køber, L., Finer, N., James, W. P. T., Sharma, A. M., Caterson, I. D., Coutinho, W. F., Gaal, L. F. V., Torp-Pedersen, C. T., & Andersson, C. (2013) · Diabetes Care · doi:10.2337/dc13-0027 · Cited by 25
Self-citationPast and present of antiobesity agents: Focus on monoamine modulators
Khorassani, F., Misher, A. D., & Garris, S. (2015) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp140034 · Cited by 26
A review of late-stage CNS drug candidates for the treatment of obesity
Heal, D. J., Gosden, J., & Smith, S. L. (2012) · International Journal of Obesity · doi:10.1038/ijo.2012.26 · Cited by 25
Yoshida, N., Numano, M., Nagasaka, Y., Ueda, K., Tsuboi, H., Tanimoto, T., & Kimura, K. (2015) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-015-0955-2 · Cited by 24
Thomas, D. D., Istfan, N. W., Bistrian, B. R., & Apovian, C. M. (2017) · Metabolism · doi:10.1016/j.metabol.2017.11.020 · Cited by 26
Gopan, G., Jose, J., Khot, K. B., & Bandiwadekar, A. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.125374 · Cited by 24
SNPs in Genes Encoding G Proteins in Pharmacogenetics
Klenke, S., & Siffert, W. (2011) · Pharmacogenomics · doi:10.2217/pgs.10.203 · Cited by 24
Peptide/Receptor Co-evolution Explains the Lipolytic Function of the Neuropeptide TLQP-21
Sahu, B. S., Rodriguez, P., Nguyen, M. E., Han, R., Cero, C., Razzoli, M., Piaggi, P., Laskowski, L. J., Pavličev, M., Muglia, L. J., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.101 · Cited by 24
Clearfield, M. B., Pearce, M., Nibbe, Y., Crotty, D. A., & Wagner, A. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0380-2 · Cited by 23
The risk of cardiovascular complications with current obesity drugs
Chao, A. M., Wadden, T. A., Berkowitz, R. I., Quigley, K., & Silvestry, F. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1806234 · Cited by 23
Oral intake of mesoporous silica is safe and well tolerated in male humans
Hagman, E., Elimam, A., Kupferschmidt, N., Ekbom, K., Rössner, S., Iqbal, M. N., Johnston, E. V., Lindgren, M., Bengtsson, T., & Danielsson, P. (2020) · PLoS ONE · doi:10.1371/journal.pone.0240030 · Cited by 23
5-HT2C Receptor Stimulation in Obesity Treatment: Orthosteric Agonists vs. Allosteric Modulators
Przegaliński, E., Witek, K., Wydra, K., Kotlinska, J. H., & Filip, M. (2023) · Nutrients · doi:10.3390/nu15061449 · Cited by 24
Overview of new antiobesity drugs
Hainer, V. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.946904 · Cited by 26
Proportional Feedback Control of Energy Intake During Obesity Pharmacotherapy
Hall, K. D., Sanghvi, A., & Göbel, B. (2017) · Obesity · doi:10.1002/oby.21978 · Cited by 22
Norepinephrine transport inhibition for treatment of vasovagal syncope
SHELDON, R. S., RITCHIE, D., MCRAE, M., & RAJ, S. (2013) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.12111 · Cited by 22
Cardiovascular Safety Outcome Trials: A meeting report from the Cardiac Safety Research Consortium
Sager, P. T., Seltzer, J. H., Turner, J. R., Anderson, J. L., Hiatt, W. R., Kowey, P. R., Prochaska, J. J., Stockbridge, N., & White, W. B. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.01.007 · Cited by 21
Bentzen, B. H., Grunnet, M., Hyveled‐Nielsen, L., Sundgreen, C., Lassen, J. B., & Hansen, H. H. (2013) · Obesity · doi:10.1002/oby.20122 · Cited by 22
Matsufuji, T., Shimada, K., Kobayashi, S., Ichikawa, M., Kawamura, A., Fujimoto, T., Arita, T., Hara, T., Konishi, M., Abe-Ohya, R., et al. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.11.018 · Cited by 22
Ceconi, C., Guardigli, G., Rizzo, P., Francolini, G., & Ferrari, R. (2011) · European Heart Journal Supplements · doi:10.1093/eurheartj/sur014 · Cited by 22
Neuropeptide receptors as potential pharmacological targets for obesity
Meneguetti, B. T., Cardoso, M. H. E. S., Ribeiro, C. F. A., Felício, M. R., Pinto, I. B., Santos, N. C., Carvalho, C. M. E., & Franco, O. L. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.002 · Cited by 23
Cardiovascular risk reduction following metabolic and bariatric surgery.
Albaugh, V. L., Kindel, T. L., Nissen, S. E., & Aminian, A. (2021) · Surgical Clinics of North America · doi:10.1016/j.suc.2020.12.012 · Cited by 21
Landgraaf, R. G., Bloem, M. N., Fumagalli, M., Benninga, M. A., de Lorijn, F., & Nieuwdorp, M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1236370 · Cited by 21
Odo, S., Tanabe, K., & Yamauchi, M. (2013) · Food and Nutrition Sciences · doi:10.4236/fns.2013.42030 · Cited by 21
Does adiponectin benefit steatotic liver transplantation?
Elias-Miró, M., Massip‐Salcedo, M., Jiménez‐Castro, M. B., & Peralta, C. (2011) · Liver Transplantation · doi:10.1002/lt.22358 · Cited by 21
Reducing the Risk of Obesity: Defining the Role of Weight Loss Drugs
Ling, H., Lenz, T. L., Burns, T. L., & Hilleman, D. E. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1277 · Cited by 21
G Protein-Coupled Receptors as Regulators of Energy Homeostasis
Tao, Y., Yuan, Z., & Xie, J. (2013) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-386933-3.00001-7 · Cited by 21
Barbadin Potentiates Long-Term Effects of Lorcaserin on POMC Neurons and Weight Loss
He, Y., Liu, H., Yin, N., Yang, Y., Wang, C., Yu, M., Liu, H., Chen, L., Wang, J., Tu, L., et al. (2021) · Journal of Neuroscience · doi:10.1523/jneurosci.3210-20.2021 · Cited by 21
Psychological Co-morbidities of Obesity
Pagoto, S., Schneider, K. L., Appelhans, B. M., Curtin, C., & Hajduk, A. M. (2011) · Springer eBooks · doi:10.1007/978-1-4419-0029-6_1 · Cited by 21
Al-Tahami, B. A. M., Ismail, A. A. A.-S., Bee, Y. T. G., Awang, S. A., Rani, W. R. W. A., Sanip, Z., & Rasool, A. H. G. (2015) · Clinical Hemorheology and Microcirculation · doi:10.3233/ch-131765 · Cited by 20
Koiou, E., Τζιόμαλος, Κ., Katsikis, I., Delkos, D., Tsourdi, E. A., & Panidis, D. (2013) · HORMONES · doi:10.14310/horm.2002.1444 · Cited by 20
Comley, R. A., Salinas, C. A., Slifstein, M., Petrone, M., Marzano, C., Bennacef, I., Shotbolt, P., van der Aart, J., Neve, M., Iavarone, L., et al. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.202895 · Cited by 20
Detection of thermogenesis in rodents in response to anti-obesity drugs and genetic modification
Arch, J. R. S., & Trayhurn, P. (2013) · Frontiers in Physiology · doi:10.3389/fphys.2013.00064 · Cited by 20
A ‘natural’ weight loss product containing sibutramine
van Hunsel, F. P. A. M., Venhuis, B. J., Keizers, P. H. J., & Kant, A. C. (2015) · Drug Testing and Analysis · doi:10.1002/dta.1925 · Cited by 20
Alsuhibani, A., Alrasheed, M., Gari, M., Hincapie, A. L., & Guo, J. J. (2022) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-021-01330-2 · Cited by 19
Treatment of non-alcoholic fatty liver disease with focus on emerging drugs
Marchesini, G., Moscatiello, S., Agostini, F., Villanova, N., & Festi, D. (2011) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2011.531700 · Cited by 20
Gorelik, E., Gorelik, B., Masarwa, R., Perlman, A., Raccah, B. H., & Matok, I. (2020) · International Journal of Obesity · doi:10.1038/s41366-020-0544-4 · Cited by 19
New Horizons: Is Obesity a Disorder of Neurotransmission?
Caron, A., & Michael, N. J. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab421 · Cited by 20
Yan, X., Pan, Y.-H., Fan, R., Song, Q., Li, S., Huang, J.-L., Li, W., Huang, D., Yuan, F.-Y., Tang, G., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00067 · Cited by 19
Sibutramine as a Cause of Sudden Cardiac Death
Guerra, M. A. R., Yadav, M., Bhandari, M., Sinha, A., Bella, J. N., & Sklyar, E. (2021) · Case Reports in Cardiology · doi:10.1155/2021/8896932 · Cited by 19
Reuptake Inhibitors of Dopamine, Noradrenaline, and Serotonin
Kintscher, U. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-24716-3_15 · Cited by 19
Effect of GLP-1 receptor agonists on weight and cardiovascular outcomes: A review
Raza, F. A., Altaf, R., Bashir, T., Asghar, F., Altaf, R., Tousif, S., Goyal, A., Mohammed, A., Mohammad, M. F., Anan, M., et al. (2024) · Medicine · doi:10.1097/md.0000000000040364 · Cited by 27
GLP-1 Receptor Agonists – Good for Body Weight, Bad for Micronutrient Status?
Kerlikowsky, F., Krämer, K., Eggersdorfer, M., & Hahn, A. (2025) · Current Developments in Nutrition · doi:10.1016/j.cdnut.2025.107587 · Cited by 18
Globular warming: how fat gets to the furnace
Williams, K. J., & Fisher, E. A. A. (2011) · Nature Medicine · doi:10.1038/nm0211-157 · Cited by 18
Recent advances in the treatment of patients with obesity and chronic kidney disease
Wahab, R. A., COHEN, R. V., & le Roux, C. W. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2203517 · Cited by 22
A review of the evidence on cardiovascular outcomes from obesity treatment
Wahab, R. A., & le Roux, C. W. (2023) · Obesity Pillars · doi:10.1016/j.obpill.2023.100071 · Cited by 18
Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article
Sidrak, W. R., Kalra, S., & Kalhan, A. (2024) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_442_23 · Cited by 21
Castro, M., Morales, M. ª. J., Olmos, M. Á. M., Pineda, J. R., Cid, L., Estévez, P., del Campo, V., & Rodríguez-Prada, J. I. (2013) · Revista Española de Enfermedades Digestivas · doi:10.4321/s1130-01082013000900004 · Cited by 18
Hiatt, W. R., Thomas, A., & Goldfine, A. B. (2012) · Circulation · doi:10.1161/circulationaha.111.023499 · Cited by 18
Protein-induced satiation and the calcium-sensing receptor
Ojha, U. (2018) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s156597 · Cited by 18
Multi-Target Drugs Against Metabolic Disorders
Scotti, L., Monteiro, A., Viana, J. D. O., Mendonça, F. J. B., Ishiki, H. M., Ernestine, N., Santos, R., & Scotti, L. (2018) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530319666181217123357 · Cited by 19
Message Distortion in Information Cascades
Ribeiro, M. H., Gligorić, K., & West, R. (2019) · International World Wide Web Conference (WWW) · doi:10.1145/3308558.3313531 · Cited by 22
Human Induced Pluripotent Stem Cells as a Screening Platform for Drug-Induced Vascular Toxicity
Tu, C., Cunningham, N. J., Zhang, M., & Wu, J. C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.613837 · Cited by 20
Analysis of Safety Alerts Associated with Dietary Supplements from Japan and Overseas
KOBAYASHI, E., Sato, Y., Umegaki, K., & Chiba, T. (2018) · Food Hygiene and Safety Science (Shokuhin Eiseigaku Zasshi) · doi:10.3358/shokueishi.59.93 · Cited by 18
Metadata
- Authors
- James, W. P. T., Caterson, I. D., Coutinho, W., Finer, N., Van Gaal, L. F., Maggioni, A. P., Torp-Pedersen, C., Sharma, A. M., Shepherd, G. M., Rode, R. A., & Renz, C. L.
- Affiliations
- London School of Hygiene & Tropical Medicine (GB)
- The University of Sydney (AU)
- Pontifícia Universidade Católica do Rio de Janeiro (BR)
- University College London (GB)
- Associazione Nazionale Medici Cardiologi Ospedalieri (IT)
- Gentofte Hospital (DK)
- University of Alberta (CA)
- Abbott (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-09-02
- Volume
- 363
- Issue
- 10
- Pages
- 905-917
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2119779723
- Cited by
- 943
- References
- 33
- Citations by year
- 2026: 27 · 2025: 43 · 2024: 50 · 2023: 40 · 2022: 35 · 2021: 50 · 2020: 45 · 2019: 36 · 2018: 54 · 2017: 38 · 2016: 63 · 2015: 69 · 2014: 75 · 2013: 91 · 2012: 93
- FWCI
- 75.02
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- UCrea (University of Cantabria) (submittedVersion, cc-by)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion, other-oa)
- ORBi (University of Liège) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Abbott Laboratories
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- University of Cambridge
- Eisai
- Novo Nordisk
- Shionogi
- Servier
- Allergan
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- sibutramine, cardiovascular outcomes, obesity, overweight, weight management, cardiovascular risk, myocardial infarction, stroke, cardiovascular mortality, type 2 diabetes, blood pressure, weight loss, older adults, drug safety, appetite suppressants, anti-obesity drugs, cardiovascular events, cardiovascular risk reduction, cardiovascular risk stratification
- MeSH terms
- Aged, Appetite Depressants, Blood Pressure, Cardiovascular Diseases, Cyclobutanes, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Humans, Male, Middle Aged, Myocardial Infarction, Obesity, Stroke, Overweight, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
